Project Grant HT9425261E378
Award Date 7/15/26
Completion Date 7/14/27
Dollars Obligated $140K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77027, USA
Similar Awards
- Federal Project Grant Award Summary Award: The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded Duke University's Office of Research Administration a Project Grant of $564,705 on September 15, 2025, for research extending through September 14, 2028. The award supports the identification of oncofusion-interacting proteins as essential drug targets for common and rare oncofusions in rhabdomyosarcoma. This research initiative aligns...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $1.1M Project Grant effective September 1, 2026, through August 31, 2030, under the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of preclinical and clinical digital twins of Ewing sarcoma (ES) and desmoplastic small round cell tumor (DSRCT) through a collaborative initiative involving academic institutions, pharmaceutical partners, and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded MD Anderson Cancer Center a $559,576 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through June 30, 2029. The grant supports a three-year investigative research project examining desmoplastic small round cell tumors (DSRCTs), specifically investigating plasticity and resistance mechanisms to improve therapeutic outcomes. This research aligns with the DHA's mission...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Children's Research Institute received a $777,659 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research titled "Use of ProResolution and Restorative Pharmacology Approaches for DMD Therapy," focusing on the development of innovative therapeutic interventions for Duchenne muscular dystrophy (DMD). The...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of California, San Francisco a $1.4 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through July 31, 2029. The award supports investigator-initiated research into the metabolic mechanisms of resistance to mutant isocitrate dehydrogenase (IDH) inhibition in gliomas. This three-year research initiative will be conducted at...
- Federal Project Grant Award Summary Children's Research Institute received a $405,341 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period August 1, 2025 through July 31, 2028. The award supports research utilizing pro-resolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy development. This research initiative advances biomedical innovation in support of the Defense...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.199 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The award funds the development and optimization of B7-H3 chimeric antigen receptor (CAR) T cells for pediatric and young adult patients with sarcomas and other B7-H3-positive solid tumors. This research initiative represents an...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $176,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research to establish a mouse model of myxoid/round cell liposarcoma with endogenous translocations. The award, effective September 1, 2025, through August 31, 2027, funds basic research aimed at advancing understanding of this rare soft tissue sarcoma through the development of a preclinical...